Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects
Status:
Completed
Trial end date:
2021-05-14
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effects of itraconazole (a strong
inhibitor of cytochrome P450 3A (CYP3A)) and rifampicin (a strong inducer of CYP3A) on the
pharmacokinetics of ASC40 in healthy volunteers.